vynetherapeutics.com (VYNE): Rasio utang marang kapitalisasi buku

VYNE Therapeutics focuses on the therapy of psoriasis and vitiligo using local BET inhibitors. The ecosystem is expanding through new clinics and VYN201 trials. The debt concentration level within the balance sheet capitalization demonstrates financial stability, where 0.00 represents the current level of the metric. High physician confidence confirms the company's status as a recognized leader in the field of immunodermatology.

Stable sales of dermatological drugs provide VYNE Therapeutics with fundamental financial stability. The current debt-to-equity ratio, which has reached 0.00, reflects the proportion of borrowed funds relative to the total value of assets. This metric measures the company's degree of dependence on creditors relative to its own equity. Amid high market competition, this indicator allows for an assessment of default risk. For the investor, the trend of this metric serves as a signal regarding the business's ability to fund marketing without compromising solvency.